(4S)-4-[2-[1-(4-fluorophenyl)-5-[3-(2,2,2-trifluoroethoxymethyl)phenyl]pyrazol-3-yl]acetyl]pyrrolidin-2-one
C24H21F4N3O3 — CID 169320354
Data last refreshed: (MolForge compound catalog, from PubChem)
About (4S)-4-[2-[1-(4-fluorophenyl)-5-[3-(2,2,2-trifluoroethoxymethyl)phenyl]pyrazol-3-yl]acetyl]pyrrolidin-2-one
(4S)-4-[2-[1-(4-fluorophenyl)-5-[3-(2,2,2-trifluoroethoxymethyl)phenyl]pyrazol-3-yl]acetyl]pyrrolidin-2-one (PubChem CID 169320354) has the molecular formula C24H21F4N3O3 and a molecular weight of 475.44 g/mol. Its IUPAC name is (4S)-4-[2-[1-(4-fluorophenyl)-5-[3-(2,2,2-trifluoroethoxymethyl)phenyl]pyrazol-3-yl]acetyl]pyrrolidin-2-one.
Molecular Properties
| Compound Name | (4S)-4-[2-[1-(4-fluorophenyl)-5-[3-(2,2,2-trifluoroethoxymethyl)phenyl]pyrazol-3-yl]acetyl]pyrrolidin-2-one |
|---|---|
| PubChem CID | 169320354 |
| Molecular Formula | C24H21F4N3O3 |
| Molecular Weight | 475.44 g/mol |
| Exact Mass | 475.15 |
| IUPAC Name | (4S)-4-[2-[1-(4-fluorophenyl)-5-[3-(2,2,2-trifluoroethoxymethyl)phenyl]pyrazol-3-yl]acetyl]pyrrolidin-2-one |
| SMILES | O=C1C[C@H](C(=O)Cc2cc(-c3cccc(COCC(F)(F)F)c3)n(-c3ccc(F)cc3)n2)CN1 |
| InChI | InChI=1S/C24H21F4N3O3/c25-18-4-6-20(7-5-18)31-21(10-19(30-31)11-22(32)17-9-23(33)29-12-17)16-3-1-2-15(8-16)13-34-14-24(26,27)28/h1-8,10,17H,9,11-14H2,(H,29,33)/t17-/m0/s1 |
| InChIKey | LQLBQHSTSFPGLT-KRWDZBQOSA-N |
| XLogP | 4.01 |
| TPSA | 73.22 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 475.44 |
| LogP ≤ 5 | 4.01 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 169320354 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.